Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia

Children receiving treatment for acute myeloid leukemia (AML) are at high risk of invasive fungal disease (IFD). Evidence from pediatric studies support the efficacy of antifungal prophylaxis in reducing the burden of IFD in children receiving therapy for AML, yet existing antifungal agents have specific limitations and comparative data to inform the optimal prophylactic approach are lacking.

Citation:
Yeoh DK, Haeusler GM, Slavin MA, Kotecha RS. Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia. Expert Rev Hematol. 2024.

Keywords:
Acute myeloid leukemia; FLT3 inhibitors; antifungal prophylaxis; hypomethylating agents; invasive fungal disease; menin inhibitors; venetoclax

Abstract:
Children receiving treatment for acute myeloid leukemia (AML) are at high risk of invasive fungal disease (IFD). Evidence from pediatric studies support the efficacy of antifungal prophylaxis in reducing the burden of IFD in children receiving therapy for AML, yet existing antifungal agents have specific limitations and comparative data to inform the optimal prophylactic approach are lacking.